tbuckley/cabot-search huggingface dataset:
Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial
Authors: Roberto Galea, Federico De Marco, Nicolas Meneveau, Adel Aminian, Frédéric Anselme, Christoph Gräni, Adrian T. Huber, Emmanuel Teiger, Xavier Iriart, Flora Babongo Bosombo, Dik Heg, Anna Franzone, Pascal Vranckx, Urs Fischer, Giovanni Pedrazzini, Francesco Bedogni, Lorenz Räber, Marco Valgimigli
Journal: Circulation (2021)

No study has so far compared Amulet with the new Watchman FLX in terms of residual left atrial appendage (LAA) patency or clinical outcomes in patients undergoing percutaneous LAA closure.In the investigator-initiated SWISS APERO trial (Comparison of Amulet Versus Watchman/FLX Device in Patients Undergoing Left Atrial Appendage Closure), patients undergoing LAA closure were randomly assigned (1:1) open label to receive Amulet or Watchman 2.5 or FLX (Watchman) across 8 European centers. The primary end point was the composite of justified crossover to a nonrandomized device during LAA closure procedure or residual LAA patency detected by cardiac computed tomography angiography (CCTA) at 45 days. The secondary end points included procedural complications, device-related thrombus, peridevice leak at transesophageal echocardiography, and clinical outcomes at 45 days.Between June 2018 and May 2021, 221 patients were randomly assigned to Amulet (111 [50.2%]) or Watchman (110 [49.8%]), of whom 25 (22.7%) patients included before October 2019 received Watchman 2.5, and 85 (77.3%) patients received Watchman FLX. The primary end point was assessable in 205 (92.8%) patients and occurred in 71 (67.6%) patients receiving Amulet and 70 (70.0%) patients receiving Watchman, respectively (risk ratio, 0.97 [95% CI, 0.80-1.16]; P=0.713). A single justified crossover occurred in a patient with Amulet who fulfilled LAA patency criteria at 45-day CCTA. Major procedure-related complications occurred more frequently in the Amulet group (9.0% versus 2.7%; P=0.047) because of more frequent bleeding (7.2% versus 1.8%). At 45 days, the peridevice leak rate at transesophageal echocardiography was higher with Watchman than with Amulet (27.5% versus 13.7%, P=0.020), albeit none was major (ie, >5 mm), whereas device-related thrombus was detected in 1 (0.9%) patient with Amulet and 3 (3.0%) patients with Watchman at CCTA and in 2 (2.1%) and 5 (5.5%) patients at transesophageal echocardiography, respectively. Clinical outcomes at 45 days did not differ between the groups.Amulet was not associated with a lower rate of the composite of crossover or residual LAA patency compared with Watchman at 45-day CCTA. Amulet, however, was associated with lower peridevice leak rates at transesophageal echocardiography, higher procedural complications, and similar clinical outcomes at 45 days compared with Watchman. The clinical relevance of CCTA-detected LAA patency requires further investigation.URL: https://www.gov; Unique identifier: NCT03399851.
Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada
Authors: Versha Banerji, Nizar Abdel-Samad, Andrew Aw, Sarah-Jane Bull, Pierre-André Fournier, Nathalie Johnson, Nicole B. Laferriere, Paola Lembo, Christina H Pelizon, Anthea Peters, Carolyn Owen
Journal: Blood (2021)
Converging 2D Nanomaterials and 3D Bioprinting Technology: State‐of‐the‐Art, Challenges, and Potential Outlook in Biomedical Applications (Adv. Healthcare Mater. 22/2021)
Authors: Hadi Rastin, Negar Mansouri, Tran Thanh Tung, Kamrul Hassan, Arash Mazinani, Mahnaz Ramezanpour, Pei Lay Yap, Le Yu, Sarah Vreugde, Dusan Losic
Journal: Advanced Healthcare Materials (2021)

3D Bioprinting In the development of advanced materials, the unique properties of 2D nanomaterials (2D NMs) have proven to be a breakthrough. Thus, the integration of 2D nanomaterials with 3D printing has led to the development of advanced bioinks with added functionality. A comprehensive review of 2D NMs' contributions to the development of advanced bioinks is presented in article number 2101439 by Dusan Losic and co-workers.
Corticothalamic feedback sculpts visual spatial integration in mouse thalamus
Authors: Gregory Born, Felix A. Schneider-Soupiadis, Sinem Erisken, Agne Vaiceliunaite, Chu Lan Lao, Milad H. Mobarhan, Martin A. Spacek, Gaute T. Einevoll, Laura Busse
Journal: Nature Neuroscience (2021)
Ethnic Variation in Hospitalized COVID-19 Patients and Correlation with Coagulopathy, Thrombosis, Prognosis and 30 Day Mortality Outcomes in California's Central Valley
Authors: Charity A Huang, Omar Mahmood, Paul Mills, Mehdia Amini, Sundeep Bekal, Jason Doornenbal, Sani Bukari, Yabby Abejie, Haifaa Abdulhaq
Journal: Blood (2021)
PD-L1 and Tumor Mutational Burden Are Not Predictive of Thrombosis in a Cohort of 1,221 Patients with Solid Organ Malignancies
Authors: Rajat Thawani, Thomas Kartika, Benjamin Elstrott, Elizabeth Batiuk, Lilian Chen, Nattapron Tun, Nicholas Taflin, Derrick Law Tao, Malinda T West, Joseph J Shatzel
Journal: Blood (2021)
COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A European Haematology Association Survey)
Authors: Francesco Marchesi, Jon Salmanton-García, Alberto Lopez-Garcia, Giulia Dragonetti, Uluhan Sili, Andreas Glenthoej, Caterina Buquicchio, Malgorzata Mikulska, Barbora Weinbergerova, Alessandro Busca, Paolo Corradini, Martin Hoenigl, Nikolay N. Klimko, Antonio Pagliuca, Francesco Passamonti, Philipp Köhler, Oliver Cornely, Livio Pagano
Journal: Blood (2021)
Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL
Authors: Nitin Jain, Hagop Kantarjian, Scott R. Solomon, Fiona He, Craig S. Sauter, Christopher R. Heery, Alan F. List, Mark C. Johnson, Yu Lou, Monika Vainorius, Koen van Besien, Adam J. Olszewski, Anthony S. Stein, Bijal D. Shah
Journal: Blood (2021)
Abstract 9549: Role of Troponin Levels, Grace Score, and Timi Score in Predicting Mortality in Covid-19 Related Myocardial Injury
Authors: Kavin raj, pranav mahajan, Monarch Shah, Jemin Jose, Abi Watts, Surya Kiran Aedma, Swati Dhobale, Riddhi Upadhyay, Adam Rizkalla, Suyansh Sharma, rukhsaar khanam, Talha Bin Farooq, Patel Keval, Randolph Martin, Hasitha Manohar
Journal: Circulation (2021)

Introduction: COVID-19 infection is associated with troponin elevation, which is associated with increased mortality. We wanted to evaluate whether troponin levels, GRACE scores, and TIMI scores were independently associated with mortality in COVID-19 patients. Methods: Out of 1500 COVID-19 patients admitted to our hospitals, 217 patients with troponin levels were included. Key variables were collected manually, and survival analysis was done. Results: Mortality was 26.5% in the normal troponin group and 54.6% in the elevated troponin group. Patients with elevated troponins had increased frequency of hypotension (P=0.01), oxygen support (P&lt;0.01), low absolute lymphocyte count (P&lt;0.01), elevated blood urea nitrogen (P&lt;0.01), higher C-reactive protein (P&lt;0.01), higher D-dimer (P&lt;0.01), higher lactic acid (P&lt;0.01), and higher qSOFA, SOFA, TIMI, and GRACE scores (all scores P&lt;0.01). On cox regression, troponin elevation (HR 1.85, 95% CI 1.18-2.88, P&lt;0.01), TIMI score &gt;3 (HR 1.79, 95% CI 1.11-2.75, P=0.01), GRACE score &gt;140 (HR 2.27, 95% CI 1.45-3.55, P&lt;0.01) were highly associated with mortality whereas cardiovascular disease (HR 1.40, 95% CI 0.89-2.21, P=0.129) and cardiovascular risk factors (HR 1.15, 95% CI 0.73-1.81, P=0.52) were not. We created four separate multivariate cox regression models for troponin, GRACE score, TIMI score, and SOFA score while adjusting for age, use of non-rebreather or high flow nasal cannula, hemoglobin&lt;8.5, suspected or confirmed source of infection, and qSOFA score. GRACE (HR 1.02, 95% CI 1.01-1.04, P&lt;0.01) and SOFA scores (HR 1.19, 95% CI 1.08-1.31, P&lt;0.01) were independently associated with mortality whereas Troponin (HR 1.08, 95% CI 0.63-1.85, P=0.76) and TIMI score (HR 1.02, 95% CI 0.99-1.06, P=0.12) were not. SOFA scores are positively correlated with GRACE scores (r=+0.39). Conclusion: Troponin elevation in COVID-19 patients is mostly due to demand ischemia rather than acute coronary syndrome-related. This was shown by the association of troponin with a higher degree of systemic inflammation and end-organ dysfunction. We recommend SOFA scores and GRACE scores in risk stratifying COVID-19 patients with myocardial injury.
Rare Cases of Infusion-Related Reactions (IRRs) Presenting As Pain Events during or after Crizanlizumab Infusion in Patients (Pts) with Sickle Cell Disease (SCD): A Systematic Evaluation of Post-Marketing (PM) Reports
Authors: Julie Kanter, Amit Shah, Vikas Joshi, Harshit Mehta, Michael Levine, Uma Arunagiri, Jincy Paulose, Breanne Donohue, Alissa Scalera, Deepa Manwani
Journal: Blood (2021)
Clonal Dynamics of Normal Haematopoiesis with Human Ageing
Authors: Emily Mitchell, Michael Spencer Chapman, Nicholas Williams, Kevin J Dawson, Nicole Mende, Emily Calderbank, Hyunchul Jung, Thomas J Mitchell, Tim Coorens, David Spencer, Heather E Machado, Henry Lee-Six, Megan Davies, Daniel Hayler, Margarete Alice Fabre, Krishnaa Mahbubani, Federico Abascal, George S. Vassiliou, Joanna E Baxter, Inigo Martincorena, Michael Stratton, David G. Kent, Krishna Chatterjee, Kourosh Saeb-Parsy, Anthony R Green, Jyoti Nangalia, Elisa Laurenti, Peter J. Campbell
Journal: Blood (2021)
Intensification of Early-Phase Therapy to Diminish the Prognostic Effect of Myeloid Antigen Expression in Infants with <i>KMT2A</i>-Rearranged Acute Lymphoblastic Leukemia: A Report from the JPLSG MLL-10 Trial
Authors: Yuki Arakawa, Takashi Ishihara, Takako Miyamura, Takao Deguchi, Masashi Sanada, Toshinori Hori, Tomomi Yamada, Yuki Aoki, Sae Ishimaru, Takayuki Takachi, Mio Yano, Shinya Sasaki, Akiko M Saito, Atsushi Manabe, Keizo Horibe, Toshihiko Imamura, Daisuke Tomizawa
Journal: Blood (2021)
Abstract 9295: Ertugliflozin Has Favorable Effects on Kidney Outcomes in Patients With Baseline Evidence of Heart Failure in VERTIS CV
Authors: David Cherney, Francesco Consentino, Samuel Dagogo-Jack, Darren K McGuire, Richard E Pratley, Robert Frederich, Mario Maldonado, Chih-Chin Liu, Christopher P Cannon
Journal: Circulation (2021)

Background: Data from VERTIS CV (NCT01986881) were analyzed to study the effect of ertugliflozin on kidney outcomes in patients with and without baseline evidence of HF. Methods: Patients with type 2 diabetes mellitus and ASCVD were randomized (1:1:1) to ertugliflozin 5 or 15 mg (both doses pooled for analyses) or placebo. Subgroups were defined by baseline history of HF or a pre-randomization left ventricular ejection fraction (EF) ≤45%. eGFR over time, total 5-year eGFR slopes and Cox proportional hazards for time to first event of a kidney composite of sustained ≥40% decrease from baseline eGFR, chronic kidney replacement therapy, or kidney death were assessed. Results: At baseline, 2439 (29.6%) had a history of HF or EF ≤45% (HF) and 5807 (70.4%) had no evidence of HF (no HF). Compared with placebo, ertugliflozin treatment resulted in a slower rate of eGFR decline in both subgroups; total placebo-adjusted 5-year eGFR slope (mL/min/1.73 m 2 /year [95% CI]): 0.96 (0.67, 1.24) and 0.95 (0.76, 1,14) for the HF and no HF subgroups, respectively (Figure 1). The HF subgroup had a higher event rate for the composite kidney outcome than the no HF subgroup. Hazard ratios (95% CI) for ertugliflozin for reducing the risk of the composite kidney outcome did not differ significantly across the two subgroups; 0.53 (0.33, 0.84) and 0.76 (0.53, 1.08) for the HF and no HF subgroups, respectively ( P interaction =0.22) (Figure 2). Conclusion: In VERTIS CV, patients with HF at baseline had a notably faster rate of eGFR decline that is unlikely to be explained by the slightly lower baseline eGFR in that group. The effects of ertugliflozin on kidney outcomes did not differ between the two groups stratified by baseline HF.
Attenuation of the Apoptosis Stimulating Protein of TP53-1 (ASPP1) Is a Predictive Marker for Therapy Resistance and Overall Survival in Acute Myeloid Leukemia (AML)
Authors: Marcus M. Schittenhelm, Max Kaiser, Vasileia Tsintari, Gunnar Blumenstock, Balazs Györffy, Kerstin Maria Kampa-Schittenhelm
Journal: Blood (2021)
Therapy Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Is Predictive of Individual Acute Myeloid Leukemia (AML) Patient Probability of Clinical Response (CR) and Overall Survival (OS): Mycare-023
Authors: Scott C Howard, Drew Watson, Michael Castro, Shweta Kapoor, Prashant Ramachandran Nair, Samiksha Avinash Prasad, Swaminathan Rajagopalan, Aftab Alam, Kunal Ghosh Roy, Diwyanshu Sahu, Deepak Anil Lala, Kabya Basu, Yashaswini S Ullal, Yugandhara Narvekar, Adity Ghosh, Mohammed Sauban, Poornachandra G, Ashish Kumar Agrawal, Anuj Tyagi, Rakhi Purushothaman Suseela, Karthik Sundara Raju, Anusha Pampana, Sanjana Patel, Nirjhar Mundkur, James Christie, Michele Dundas Macpherson, Guido Marcucci
Journal: Blood (2021)
CCS1477, a Novel p300/CBP Bromodomain Inhibitor, Enhances Efficacy of Azacitidine and Venetoclax in Pre-Clinical Models of Acute Myeloid Leukaemia and Lymphoma
Authors: Nigel Brooks, Tomasz Knurowski, Andrew Hughes, Karen Clegg, William West, Neil A Pegg, Gary J Spencer, John Chadwick, Tim C.P Somervaille
Journal: Blood (2021)
Preclinical Activity of the Clinical Stage Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Splicing Mutant Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Authors: Leya Y Schwartz, Gaurav S Choudhary, Nandini Ramachandra, Srabani Sahu, Shanisha Gordon, Bruce Ruggeri, Diane Heiser, Peggy Scherle, Daniel Starczynowski, Amit Verma
Journal: Blood (2021)
Abstract 9484: Ferroptosis Inhibitors Reduce Brain Inflammation Due to Cardiac Ischemia/Reperfusion Injury in Rats
Authors: Suchan Liao, Ying Luo, Jun Wu, Titikorn Chunchai, Benjamin Ongnok, Thawatchai Khuanjing, Juthipong Benjanuwattra, Nattayaporn Apaijai, Nipon Chattipakorn, Siriporn Chattipakorn
Journal: Circulation (2021)

Introduction: Brain inflammation and microglial hyperactivation are involved in the process of neuronal death including apoptosis, necroptosis, and ferroptosis, following cardiac and cerebral ischemia/reperfusion (I/R) injury. However, the roles of these cell death inhibitors on brain inflammation and microglia following cardiac I/R injury have not been investigated. Hypothesis: Inhibitors of apoptosis, necroptosis and ferroptosis effectively attenuate brain inflammation and microglial hyperactivation in rats with cardiac I/R injury. Methods: Rats were subjected to either sham or cardiac I/R operation (30 min-ischemia followed by 120-min reperfusion). Rats in cardiac I/R group were divided into 4 treatment groups: 1) vehicle, 2) apoptosis inhibitor (Z-VAD; 3.3 mg/kg), 3) necroptosis inhibitor (necrostatin-1; Nec-1; 3.3 mg/kg), and 4) ferroptosis inhibitor (ferrostatin-1; Fer-1; 2 mg/kg). These drugs were given intravenously at 15 min before ischemia. Finally, the heart and brain tissues were removed and used to determine cardiac infarct size, hippocampal-microglial morphology, and levels of cortical inflammatory cytokines. Results: Cardiac I/R injury caused myocardial infarction and brain inflammation as indicated by increased cortical IL-1β mRNA level and hippocampal microglial hyperactivation. Treatment with Z-VAD and Fer-1, but not Nec-1, reduced myocardial infarction and cortical IL-1β mRNA level. Z-VAD and Fer-1 also increased microglial process length and decreased microglial volume. Nec-1 increased microglial process length, but it did not decrease microglial volume. All treatments similarly decreased microglial number and increased microglial complexity after I/R injury (Fig 1) . Conclusions: Inhibition of apoptosis and ferroptosis, but not necroptosis, effectively reduced myocardial infarction and brain inflammation. Targeting these cell death pathways could be a novel strategy against brain injury due to cardiac I/R.
Abstract PO-044: Mechanobiological analysis of human patient pancreatic cancer tissues and the effect of cellular transmembrane mucins on glycocalyx-actomyosin mechanics
Authors: Andrew Massey
Journal: Cancer Research (2021)

Abstract Pancreatic cancer is one of the most lethal malignancies with a 5-year survival rate currently below 10%. Unfortunately, current diagnostic methods are unable to readily recognize early disease progression, and symptoms are commonly misdiagnosed. Therefore, determining novel biomarkers related to disease progression remains an important area of research. Transmembrane mucins, a major component of the cellular glycocalyx, normally play a protective role in epithelial tissues; they are also known to be overexpressed in various cancers, including pancreatic. In addition, mucins are known to increase aggressiveness, enhance drug resistance, and reduce survivability in cancers where they are upregulated. Although the biochemical effects of mucins are well understood, there is minimal research into how they affect cancer cells at a biophysical level. Recently, there has been great interest in examining the biophysical properties of cancer cells. The current consensus is that cancerous cells are softer than their normal counterparts, and that more metastatic cells become softer compared to more benign tumor cells. Measuring these physical properties could potentially give clinicians a more rapid way to diagnose tumors, determine the course of disease progression, physically determine the effect of a biomolecule when its expression is altered, or determine the efficacy of various chemotherapeutics. In this study, we will first use atomic force microscopy-based nanomechanical mapping to measure the biophysical differences between normal cells, cancerous cells, and the extracellular matrix extracted from human patient tumor tissues and track the measured changes, both before and after chemo treatments. Our preliminary in vitro results suggest that 2D-adherent human cancerous pancreatic cells are indeed softer than their normal counterparts, in agreement with the literature. In addition, modulation of the glycocalyx architecture via hyaluronidase treatment leads to considerable changes in cellular stiffness in both normal and cancerous cells, implying a link between the glycocalyx and the underlying actomyosin skeleton. Future studies will examine the in vitro effects of specific transmembrane mucins. Using overexpression and knockdown transfection models, the impact on cellular mechanics, as well as structural changes in the glycocalyx and actomyosin cortex, will be analyzed in pancreatic cancer cells to determine how these mucins effect cellular mechanics and by extension regulate tumorigenesis and metastasis. Citation Format: Andrew Massey. Mechanobiological analysis of human patient pancreatic cancer tissues and the effect of cellular transmembrane mucins on glycocalyx-actomyosin mechanics [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-044.
The Impact of Non-Clinical Factors in Clinical Trial Enrollments of Patients with Hematologic Malignancies
Authors: Jamile M. Shammo, Anne Timmermann, Deborah A. Katz, Agne Paner, Seo-Hyun Kim, Irene dehghan-Paz, Melissa L. Larson, Parameswaran Venugopal, Celalettin Ustun, Ankur Varma, Sunita Nathan
Journal: Blood (2021)
Comparative Analysis of Mature T-Cell and NK/T-Cell Lymphomas in Patients with and without HIV: Results from the NA-Accord and Complete Cohorts
Authors: Min Jung Koh, Mwanasha H. Merrill, Min Ji Koh, Robert N. Stuver, Carolyn D. Alonso, Francine M. Foss, Angel M. Mayor, M. John Gill, Marta Epeldegui, Edward Cachay, Jennifer E. Thorne, Michael J. Silverberg, Michael A. Horberg, Keri N. Atlhoff, Ank E. Nijhawan, Kathleen A. McGinnis, Charles S. Rabkin, Sonia Napravnik, Changyu Shen, Salvia Jain
Journal: Blood (2021)
Pharmacologic Inhibition of SUMO-Activating Enzyme Potentiates Interferon Response and T Cell-Mediated Anti-Tumor Immunity in Chronic Lymphocytic Leukemia (CLL) and Lymphoma Models
Authors: Vi Lam, Xiaoguang Wang, Scott R Best, Nur Bruss, Tingting Liu, Olga Danilova, Tanya Siddiqi, Nathan Pennock, Alexey V. Danilov
Journal: Blood (2021)
Ann Robinson’s research reviews—12 November 2021
Authors: Ann Robinson
Journal: BMJ (2021)

This US case series study found a slightly increased risk of Guillain-Barre syndrome (GBS) in the six weeks after a non-live recombinant zoster vaccine (RZV) was given to Medicare patients over 65 years old, compared with patients who had zoster vaccine live (ZVL), with a rate ratio of 2.34.1 The risk of GBS in the six weeks immediately after vaccination was higher than during a control window of six weeks to six months after vaccination (rate ratio 2.84). There are some potential limitations in the study, such as the possibility of confounders, shingles jabs given outside of the Medicare system, and having to guess the risk window for GBS associated with RZV. The results don’t apply to the UK, where only adults aged 70-79 years are offered shingles vaccination and most get a single dose of ZVL (Zostavax), whereas the US now offers two doses of RZV (Shingrix) to eligible adults aged over 50. GBS is generally rare (1 to 2 cases per 100 000 person-years), and shingles can be nasty, so even with the excess cases estimated at 3 per million doses of RZV, the risk-benefit …
Covid vaccination to be mandatory for NHS staff in England from spring 2022
Authors: Abi Rimmer
Journal: BMJ (2021)

Covid vaccination to be mandatory for NHS staff in England from spring 2022 Abi RimmerEngland's health and social care secretary has announced that all staff who work in health and social care settings regulated by the Care Quality Commission will have to be fully vaccinated against covid-19 by 1 April 2022.
Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry
Authors: Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy, Guillaume Cartron, David Beauvais, Fabien Le Bras, Francois Xavier Gros, Sylvain Choquet, Pierre Bories, Pierre Feugier, Rene-Olivier Casasnovas, Jacques-Olivier Bay, Mohamad Mohty, Magalie Joris, Thomas Gastinne, Pierre Sesques, Jean Jacques Tudesq, Laetitia Vercellino, Franck Morschhauser, Elodie Gat, Florence Broussais, Roch Houot, Catherine Thieblemont
Journal: Blood (2021)
White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance)
Authors: Michael P. Ozga, Deedra Nicolet, Krzysztof Mrózek, Christopher J. Walker, James S. Blachly, Jessica Kohlschmidt, Shelley Orwick, Andrew J Carroll, Richard A. Larson, Jonathan E Kolitz, Bayard L. Powell, Richard M. Stone, John C. Byrd, Ann-Kathrin Eisfeld, Alice S. Mims
Journal: Blood (2021)
The Spliceosome As a New Therapeutic Target in Cytarabine-Resistant Acute Myeloid Leukemia
Authors: María Luz Morales, Roberto Garcia-Vicente, Alba Rodríguez García, Noemí Álvarez Sánchez-Redondo, Alejandra Ortiz-Ruiz, Armando Reyes-Palomares, Ricardo Sanchez, Vanesa Garrido-Garcia, Gonzalo Carreño-Tarragona, Sylvie Hermouet, Rosa Ayala, Joaquin Martinez Lopez, María Linares
Journal: Blood (2021)
A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
Authors: Ing S Tiong, Sun Loo, Emad Uddin Abro, Devendra Hiwase, Shaun Fleming, Ashish Bajel, Emma Palfreyman, Chun Yew Fong, Tse-Chieh Teh, Adam Ivey, Andrew H. Wei
Journal: Blood (2021)
Identifying Mechanisms Associated with Venetoclax Resistance in Multiple Myeloma (MM)
Authors: Yuan Xiao Zhu, Laura Ann Bruins, Joseph Ahmann, Cecilia Bonolo De Campos, Esteban Braggio, Xianfeng Chen, Mariano Arribas, Susie Darvish, Gregory J Ahmann, Rafael Fonseca
Journal: Blood (2021)